drugset / Trial / NCT01093729
A Study of HM11260C in Healthy Male Subject
RandomizedSingle-groupTriple-blindTreatment
Summary
Study Design: Randomized, double-blind, placebo-controlled, escalating single-dose design. Five ascending dose cohorts are planned.
Timeline
- Start
- 2010-02
- Primary completion
- 2010-10
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efpeglenatide | Peptide | 0.5 ug/kg | Subcutaneous |
| Subject | Efpeglenatide | Peptide | 2 ug/kg | Subcutaneous |
| Subject | Efpeglenatide | Peptide | 4 ug/kg | Subcutaneous |
| Subject | Efpeglenatide | Peptide | 8 ug/kg | Subcutaneous |
| Subject | Efpeglenatide | Peptide | 14 ug/kg | Subcutaneous |
Indications
No indication recorded.